Recent data: in over half of studies, site selection to full activation takes 5+ months, and 39% say timelines have worsened vs. two years ago — with sponsor-CRO communication rated average/poor by 47%. Earlier research put overall trial delay rates as high as 86%.

Where it typically breaks down:

• Protocol design that’s scientifically sound but operationally unrealistic — visit burden and IMP logistics never stress-tested against real site capacity. A common issue: misalignment between local Standard of Care and the protocol’s treatment/assessment schedule. “Per SoC” gets interpreted differently across countries, and mismatches in visit cadence, comedication rules, or washouts surface late at EC review — triggering costly amendments.
• KOL and country selection driven by reputation rather than genuine feasibility fit — regulatory maturity, patient density, and real experience with the pathway.
• CTIS vs. non-CTIS realities. CTIS was built for a ~60-day Part I/II review. In practice, average EU approval still runs 110+ days, vs. 30–60 days elsewhere — driven by inconsistent Member State requirements and Part I/II gaps. Non-CTIS countries (Western Balkans, parts of CEE, CIS) follow different EC/RA logic — a “CTIS mindset” there is costly.
• Vendor contracting lagging the regulatory track instead of running parallel — labs, IRT, drug supply, imaging vendors contracted late become the hidden critical path.
• Site activation & FPI — readiness too often assumed, not verified. Sites can look approved on paper and be unprepared in practice. A related driver: weak site qualification combined with Client pressure to activate sites the CRO’s own assessment would flag as back-up-tier. Pushing a back-up site into the primary list rarely saves time — it relocates the delay into slower contracting, EC/RA turnaround, or a longer gap to FPI.

None of this is one failure — it’s interdependent gaps across protocol, site capacity, approval and contracting, compounded by sponsor-CRO misalignment. Budget gaps alone can add weeks to activation.

This is the gap Nushev Biotech Advisory works in.

We sit between sponsor strategy and CRO execution — stress-testing protocol feasibility, matching country/site/KOL selection to real fit (CTIS and non-CTIS alike), sequencing vendor contracting against the regulatory path, and auditing site readiness before it becomes an FPI surprise.

Heading into study start-up and want a second set of eyes on the plan — before the timeline slips, not after? Let’s talk.

#ClinicalTrials #ClinicalOperations #CTIS #ClinicalResearch #Biotech #StudyStartUp #CRO

Posts live in the _posts/ folder as Markdown files, named YYYY-MM-DD-title.md. Each one starts with a short front-matter block (the part between --- lines) setting the layout, title, and date, and everything below that is written in plain Markdown — headings, bold, italics, links, lists, and so on.

How to add a new post

1. Create a new file in _posts/, named with today’s date and a short slug, e.g. 2026-09-20-fundraising-in-a-tight-market.md.
2. Add the front matter block at the top (copy this post’s as a starting point).
3. Write the post body in Markdown below it.
4. Commit it to the repository — GitHub Pages will automatically rebuild the site and the post will appear on the Blog page, newest first.

No other files need to change — the blog listing page picks up every post automatically.

Small-to-mid biotechs — who are behind an estimated 40% of new FDA drug approvals — often can’t justify a full-time clinical development executive, yet still need senior-level oversight to get a program investor-ready.

Consultancies and CROs running FSP models frequently need flexible surge capacity or regional delivery reach (particularly across Southeast Europe/CEE) that’s slow and expensive to build internally.

That’s the gap Nushev Biotech Advisory is built around — not a fixed-scope engagement, but a model that flexes to how each partner actually wants to work:

• Fractional leadership for biotechs that need senior clinical development oversight, without a full executive hire
• Subcontracted delivery for consultancies and CROs that need regional CRO/CRA coverage, without building it themselves
• Referral and joint go-to-market partnerships for organizations that want to extend reach without adding headcount

Backed by 20+ years across CRO and pharma environments (Novartis, IQVIA, WCG, Advanced Clinical), with long-term experience across the US, UK, and EU, and hands-on regional depth in Serbia, Bosnia & Herzegovina, Montenegro, North Macedonia, and Bulgaria — the reach to support engagements globally, plus the specific markets where partners most often need extra capacity.

If any of this sounds like a gap in how your organization is currently resourced, let’s talk. Happy to share more detail — including my CV — on request.

#ClinicalDevelopment #Biotech #CRO #FSP #LifeSciences #ClinicalTrials